What the evidence actually says about duration

Published peer-reviewed data on ChondroFiller™ currently extend to 36 months — and at that horizon, the evidence is both strong and reassuring. The prospective post-market follow-up study most frequently cited in the manufacturer's Clinical Evaluation Report (CER, April 2025) recorded sustained functional improvement at the three-year mark, with gains that held firm rather than declining after the first year. The pattern the data describes is one of plateau and hold: benefit consolidates over the first 6–12 months and then remains stable.

A 3–5 year durability range is quoted in some clinical summaries and overview sources. The three-year end of that range is grounded in peer-reviewed published evidence; the five-year figure is not currently supported by a primary published clinical trial and should be understood as the upper estimate from clinical experience rather than a rigorously demonstrated endpoint.

Individual outcomes are not guaranteed. Durability is shaped by factors including the patient's age and activity level, the size and grade of the cartilage defect, and the quality of surrounding tissue — all of which affect how well the repair process establishes itself. Those factors are covered in detail later in this article. For most suitable patients, however, published evidence supports the expectation of meaningful, durable benefit lasting at least to the three-year horizon.

Why the scaffold is designed to outlast itself

Unlike hyaluronic acid viscosupplementation or a cushioning hydrogel, ChondroFiller™ is not designed to remain in the joint indefinitely. That distinction is central to understanding why its results can persist well beyond the life of the original material.

The scaffold is an acellular Type I collagen matrix that, once placed under ultrasound guidance during an outpatient appointment, sets at the defect site in approximately 3–5 minutes. From that point it begins a gradual process of biological resorption over roughly 1–2 years. Rather than functioning as a persistent implant, it serves as a temporary structural framework that the body progressively replaces with its own repair tissue. The durability being measured in clinical follow-up is therefore biological — the question is whether that repair tissue holds, not whether the original collagen material remains.

That cell migration actually occurs — rather than being a theoretical expectation — is directly supported by a 2025 ex vivo study that measured a 2.4-fold increase in DNA content within the scaffold by day 14. This rise in cellular material confirms that host cells are actively colonising the matrix as it begins to degrade, providing concrete mechanistic evidence for the process the scaffold is designed to initiate.

Evidence suggests repair tissue can form and stabilise within the defect across that 1–2 year maturation window — and it is the quality and persistence of that tissue, rather than any property of the collagen gel itself, that underpins the durability reported in clinical series.

What the clinical outcome data shows

The most cited anchor in the clinical evidence base is a prospective post-market clinical follow-up (PMCF) study by Jerosch et al., which tracked patients to 36 months. Its headline finding: a mean improvement of 32.4 points on the International Knee Documentation Committee (IKDC) score — a validated patient-reported measure of knee pain, function, and activity — with the cohort reaching an average absolute score of 80. That gain was sustained, and marginally increased, at the three-year mark rather than declining from its earlier peak.

To understand why that figure matters, it helps to know what the IKDC's threshold for clinical significance is. A change of 16.7 points is the Minimal Clinically Important Difference (MCID) — the minimum shift that patients actually notice as a meaningful improvement in daily life. Across all four knee studies in the published ChondroFiller evidence base, every single study exceeds this threshold, meaning the benefit recorded is not a statistical artefact but a real-world change patients can feel.

Clinical summaries report that 70–85% of treated patients achieve meaningful symptom relief across knee, hip, and small-joint applications, described at a three-to-five year horizon. That range reflects aggregated clinical experience rather than a single primary trial, and should be interpreted with that in mind.

On safety, published data report complication rates close to zero and a reoperation rate of approximately 3–8%. For context, reoperation rates following microfracture can reach as high as 41% in published series — a difference worth knowing, even if individual circumstances vary and no direct comparison can substitute for a personalised clinical assessment.

What MRI scans show about structural repair

MOCART — Magnetic Resonance Observation of Cartilage Repair Tissue — is the validated scoring tool used to quantify repair tissue quality on MRI, assessing dimensions such as defect fill, tissue integration, and surface regularity on a scale up to 100.

In European clinical studies, scores followed a clear trajectory. At four weeks post-injection, MOCART averaged 65.3 — early filling, with repair tissue present but still maturing. By twelve months that figure had risen to 81.6, reflecting substantial defect filling and progressive consolidation of new tissue within the defect. Beyond year one, scores held within a range of 81.6 to 84.3 across the follow-up periods studied, with no evidence of structural deterioration at the imaging level.

A score above 80 corresponds to greater than 80% defect filling with good integration into the surrounding native cartilage — a threshold indicating that the repaired area is not merely occupied but structurally incorporated into the joint surface.

The stability of MOCART scores after year one is arguably the most important imaging finding: repair tissue visible on MRI at twelve months appears, at cohort level, to persist rather than break down across the follow-up periods studied. That is tissue-level evidence that symptom scores alone cannot provide.

Who tends to get the most durable results

Durability figures from clinical studies represent cohort averages — and the patients who make up those cohorts matter. The published evidence consistently points to a specific profile where results are most likely to hold: younger, active individuals with small, focal, isolated cartilage lesions graded III or IV on the standard scale, surrounded by healthy native cartilage with intact borders.

Mazek, writing in the Journal of Hip Preservation Surgery in 2021, identified two factors most strongly associated with good short-term outcomes: a shorter duration of pre-operative symptoms before treatment, and a good scaffold fill grade at the time of injection. Both findings have practical implications. On symptom duration, the message is that earlier treatment — before surrounding joint health deteriorates — may support better repair. On fill grade, the quality of image-guided scaffold placement is not a minor procedural detail; it is part of the durability equation.

The evidence base does not cover diffuse or advanced osteoarthritis. ChondroFiller is indicated for focal cartilage defects — discrete, contained lesions — not widespread joint degeneration. Patients with diffuse OA represent a different clinical scenario, and applying the published outcome figures to that population would be misleading. A contained lesion with healthy borders provides the biological environment that allows repair tissue to integrate properly; without that environment, the scaffold has less to work with.

Whether an individual's lesion fits this profile is a question for clinical assessment rather than self-diagnosis.

The honest limits of what the evidence covers

The published outcome data is genuinely encouraging — but three things the evidence cannot yet answer deserve straightforward acknowledgment.

None of the published ChondroFiller studies are independent randomised controlled trials. Every study in the current evidence base is either a manufacturer-commissioned post-market clinical follow-up (PMCF) or an author-level clinical evaluation. That is not atypical for a Class III device at this stage of its commercial lifespan, and it does not invalidate the findings — but it does mean the outcome figures have not yet been tested against an independent control group using a standardised comparator arm.

For patients who respond well and consider a repeat injection, the picture is similar: clinical summaries describe repeat dosing as safe, but no published trial has been specifically designed to study it. That remains an open gap — clinical consensus, not established evidence.

The UK patient population represented in these studies is also largely self-selecting. Because ChondroFiller is not NHS-funded and is not covered by major UK private medical insurers, those who have been treated tend to be patients actively pursuing a privately funded pathway from around £3,000 per box. That profile may not reflect the full range of people who could benefit, and outcome figures should be read with that context in mind.

Post-market clinical follow-up programmes continue to accumulate data — a regulatory requirement for Class III devices. The finding that would most change what patients can reasonably expect is whether the structural repair confirmed on MRI at twelve months holds at the four- or five-year mark: that is the specific question the next published cohort needs to answer.